Nebivolol 5mg Tablet in PCD Pharma Franchise in Ahmedabad

Nebivolol 5mg Tablet in Pharmaceutical Manufacturing Company in Mumbai

Nebivolol 5mg Tablet in Cardiac Care Pharma Franchise in Hyderabad

Nebivolol 5mg Tablet in Pharma Distributors & Suppliers in Delhi

Nebivolol 5mg Tablet in Pharma Export Company in Chennai
Nebivolol 5mg Tablet in Pharma Franchise Opportunity in Bengaluru

Home/Products /nebivolol-5-mg-tablet

About the Product

Description


Nebiroll 5 mg Tablet is a third-generation beta-1 selective adrenergic blocker with additional nitric oxide (NO)-mediated vasodilatory effects. This unique dual mechanism reduces heart rate and myocardial oxygen demand while simultaneously promoting vasodilation and improving arterial compliance. Compared to older beta-blockers, Nebivolol has a more favorable safety profile, causing less fatigue, fewer metabolic side effects, and minimal impact on sexual function. The 5 mg strength is the standard therapeutic dose used in adults for managing hypertension and certain cardiac conditions. By improving endothelial function and reducing oxidative stress, Nebivolol provides additional cardiovascular protection beyond simple blood pressure control, making it especially useful in patients with comorbid conditions such as diabetes or metabolic syndrome.

Common side effects include headache, dizziness, fatigue, and bradycardia (slow heart rate). Some patients may experience mild gastrointestinal disturbances, sleep disturbances, or cold extremities. Rare but serious adverse effects include severe hypotension, worsening of heart failure, atrioventricular block, or bronchospasm in sensitive individuals. Compared to non-selective beta-blockers, Nebivolol has a lower risk of respiratory and metabolic side effects.

Nebivolol 5 mg Tablet is indicated for the treatment of essential hypertension in adults, either as monotherapy or in combination with other antihypertensives. It is also used in selected patients with stable chronic heart failure with reduced ejection fraction (HFrEF) as part of a comprehensive management plan.

Nebivolol 5 mg should be used only under medical supervision. It is contraindicated in patients with severe bradycardia, second- or third-degree heart block, cardiogenic shock, or severe liver impairment. Caution is required in patients with asthma, COPD, peripheral vascular disease, diabetes, or thyroid disorders. The dose should not be stopped abruptly, as sudden discontinuation can cause rebound hypertension or exacerbate angina and heart failure. It is not recommended during pregnancy or breastfeeding unless prescribed by a physician after careful risk assessment. Alcohol consumption should be limited, as it can potentiate the blood pressure-lowering effect and increase dizziness. Regular monitoring of blood pressure, heart rate, and overall cardiac status is essential during long-term therapy.

Store Nebivolol 5 mg Tablet in a cool, dry place below 30°C. Protect from direct sunlight and moisture. Keep the tablets in their original packaging and out of the reach of children. Do not use the medication beyond the expiry date printed on the strip or container.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Nebivolol 5 mg Tablets in the PCD pharma franchise market?

Nebivolol Tablets have strong demand in the cardiology and antihypertensive segment, making them a high-value prescription product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for hypertension, cardiovascular risk reduction, and long-term heart health management, ensuring consistent repeat prescription demand.

Why should medical distributors include Nebivolol 5 mg Tablets in their product range?

Medical distributors and agencies benefit from the rising prevalence of hypertension and cardiovascular disorders. Effectively helps control high blood pressure (hypertension) Supports long-term cardiovascular protection and heart health Helps reduce heart rate and cardiac workload Selective beta-blocker with a well-established role in hypertension management Widely prescribed by cardiologists and general physicians Suitable for long-term daily therapy Strong demand in hospital, clinic, and retail pharmacy segments This makes it a high-demand chronic cardiovascular care product with excellent repeat prescription potential.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Nebivolol 5 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and franchise partners benefit from consistent cardiology prescription demand, long-term patient adherence, strong physician confidence, and stable year-round turnover in the cardiovascular segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete cardiology and antihypertensive product portfolio access to build a strong presence in the cardiovascular healthcare market.